Weight Loss Peptides and Muscle Loss: The Problem, the Science, and How to Protect Lean Mass
GLP-1 drugs produce dramatic fat loss — but 25-40% of weight lost is muscle. New combinations like bimagrumab + semaglutide and next-gen drugs like retatrutide may change that equation.
Research Digest8 min readApril 7, 2026
The Muscle Problem
Here's the uncomfortable truth about the most effective weight loss drugs ever developed: they don't just burn fat. Data from the STEP 1 trial shows that approximately 39% of weight lost on semaglutide 2.4mg is lean mass — not fat. The SURMOUNT-1 body composition substudy found similar proportions for tirzepatide: roughly one-third of weight lost was lean mass.
At the population level, this means a patient who loses 30 pounds on semaglutide might lose 11-12 pounds of muscle along with 18-19 pounds of fat. A systematic review of semaglutide trials confirmed that lean mass loss ranges from 25-40% of total weight lost across studies.
This matters because muscle mass is metabolically active tissue — it drives resting metabolic rate, insulin sensitivity, functional capacity, and long-term weight maintenance. Losing it makes weight regain more likely and can compromise physical function, especially in older adults.
Bimagrumab + Semaglutide: The BELIEVE Trial Breakthrough
The most exciting development in muscle-preserving weight loss comes from the BELIEVE trial, published in Nature Medicine in March 2026. This Phase 2 study of 507 adults tested bimagrumab (an anti-activin type II receptor antibody that blocks myostatin signaling) combined with semaglutide.
The results were striking. Semaglutide 2.4mg alone produced 15.7% weight loss but with 7.4% lean mass loss. Bimagrumab alone produced 10.8% weight loss with a 2.5% lean mass increase. The high-dose combination achieved 22.1% weight loss with only 2.9% lean mass loss — and 92% of the weight lost was fat.
The combination also drove deeper adiposity improvements: 45.7% total fat mass reduction and 58.2% visceral fat reduction, compared to 27.8% and 35.8% with semaglutide alone. This is the closest any therapy has come to the ideal of "pure fat loss" in a clinical trial.
Bimagrumab works by blocking activin type II receptors, preventing myostatin and activin from suppressing muscle growth — essentially removing the brake on muscle preservation while GLP-1 agonism drives fat loss. The combination addresses both sides of the body composition equation simultaneously.
Retatrutide: Does Triple Agonism Help?
Retatrutide (Eli Lilly's investigational triple GIP/GLP-1/glucagon agonist) is being closely watched for body composition effects. The glucagon receptor component increases energy expenditure and hepatic fat oxidation — mechanisms that could theoretically shift the weight loss ratio toward fat and away from muscle.
A Phase 2 body composition substudy in patients with type 2 diabetes showed favorable body composition changes with retatrutide. However, no head-to-head data comparing retatrutide's lean mass preservation to semaglutide or tirzepatide has been published yet from the Phase 3 TRIUMPH program.
A comprehensive review in Metabolism noted that the glucagon receptor component's thermogenic effect — increasing energy expenditure rather than just reducing intake — could be mechanistically advantageous for lean mass preservation. The reasoning: if more of the caloric deficit comes from increased expenditure rather than reduced intake, the body may be less inclined to catabolize muscle for energy. This remains theoretical until comparative body composition data is published.
Resistance Training: The Most Proven Strategy
While pharmaceutical solutions are advancing, the most immediately available muscle preservation strategy is resistance exercise. The S-LITE trial (published in NEJM) randomized patients to exercise, liraglutide, both combined, or placebo. The combination of exercise + liraglutide best preserved lean body mass while maintaining weight loss.
A 2024 review in Diabetes Care specifically addressed whether resistance exercise can optimize body composition during incretin-based therapy, concluding that structured resistance training is the most evidence-supported intervention for lean mass preservation during GLP-1 weight loss.
A clinical strategy review in Obesity Reviews outlined practical recommendations: resistance training 2-3 times per week targeting all major muscle groups, progressive overload to maintain stimulus, and adequate recovery between sessions. The authors emphasized that starting exercise early in the weight loss process — not waiting until significant weight has been lost — produces better lean mass outcomes.
Protein: The Dietary Foundation
Higher protein intake during caloric restriction is one of the most robustly supported strategies for lean mass preservation. A meta-analysis of 24 randomized controlled trials found that high-protein diets (approximately 1.2-1.6 g/kg/day) during energy restriction preserved significantly more lean mass — 0.47 kg less lean mass lost on average — and produced greater fat mass loss compared to standard-protein diets.
This is particularly relevant for GLP-1 users because these drugs reduce appetite and total food intake. If protein intake drops proportionally with overall calories, muscle loss accelerates. Patients on semaglutide or tirzepatide should prioritize protein at every meal, aiming for at least 1.2 g/kg of body weight daily, with 1.6 g/kg as a higher target for those doing resistance training.
Practical strategies: protein-first eating (start each meal with the protein portion), protein supplementation if appetite is severely suppressed, and distributing protein across 3-4 meals rather than concentrating it in one. A 2025 review of dietary supplement considerations during GLP-1 therapy also discussed creatine, vitamin D, and omega-3s as adjuncts, though clinical trial data specifically combining these supplements with GLP-1 drugs is still limited.
The Emerging Landscape
The muscle preservation problem is driving a wave of pharmaceutical innovation beyond bimagrumab:
CagriSema (cagrilintide + semaglutide, Novo Nordisk) combines an amylin analog with semaglutide and has shown 22-24% weight loss — roughly 7-8% more than semaglutide alone. Whether the amylin component specifically preserves lean mass hasn't been established in published body composition substudies yet, but it's being actively investigated.
Myostatin inhibitors and activin receptor antibodies (the class bimagrumab belongs to) are being explored both as standalone treatments and as combination partners for GLP-1 drugs. The BELIEVE trial opens the door for this combination approach.
Follistatin, a natural activin-binding protein that inhibits myostatin, is discussed in the peptide therapy community for similar reasons — though its clinical evidence for muscle preservation during weight loss is limited to preclinical data.
The field is moving from "how much weight can we lose" to "how can we ensure the weight we lose is fat, not muscle" — a fundamentally more sophisticated question that may define the next generation of obesity therapy.
What You Can Do Now
While waiting for next-generation combination therapies, the evidence supports several practical strategies for anyone on GLP-1 weight loss drugs:
Resistance train at least 2-3 times per week. This is the single most impactful intervention for muscle preservation. Focus on compound movements (squats, deadlifts, presses, rows) that recruit large muscle groups.
Prioritize protein at 1.2-1.6 g/kg/day. This means 90-120g of protein daily for a 75kg person. Protein-first eating helps when appetite is suppressed.
Start early. Begin resistance training and protein optimization before or at the start of GLP-1 therapy, not months into weight loss when lean mass has already been lost.
Monitor body composition, not just scale weight. DXA scans, bioimpedance, or even waist-to-hip ratio provide more meaningful data than the scale alone.
Discuss with your clinician. If lean mass preservation is a priority, they may consider dose adjustments, slower weight loss targets, or adding agents that support muscle maintenance. The evidence base for combination approaches is growing rapidly.
Key Findings
- 25-40% of weight lost on semaglutide and tirzepatide is lean mass (muscle), not fat
- The BELIEVE trial (Nature Medicine, 2026): bimagrumab + semaglutide achieved 22.1% weight loss with 92% from fat and only 2.9% lean mass loss vs 7.4% with semaglutide alone
- Retatrutide's glucagon receptor component may theoretically favor fat loss over muscle loss through increased energy expenditure, but head-to-head body composition data is pending
- The S-LITE trial (NEJM) showed exercise + GLP-1 therapy best preserved lean mass during weight loss
- High-protein diets (1.2-1.6 g/kg/day) preserve significantly more lean mass during caloric restriction across 24 RCTs
- Visceral fat reduction was 58.2% with bimagrumab + semaglutide vs 35.8% with semaglutide alone
Limitations & Caveats
- The BELIEVE trial is Phase 2 — bimagrumab + semaglutide is not yet approved; Phase 3 trials are needed
- Retatrutide body composition data is from a Phase 2 substudy — no head-to-head lean mass comparison with semaglutide exists
- Most resistance training + GLP-1 data comes from liraglutide studies, not semaglutide or tirzepatide specifically
- Protein intake recommendations are extrapolated from general weight loss literature, not GLP-1-specific RCTs
- Long-term effects of lean mass loss during GLP-1 therapy on functional outcomes and weight regain are not fully characterized
- Bimagrumab has side effects (muscle spasms, acne) that may limit tolerability in some patients
Sources
101.2.3.4.5.6.7.8.9.10.
Bimagrumab Plus Semaglutide Alone or in Combination for the Treatment of Obesity: A Randomized Phase 2 Trial (BELIEVE)
Phase II RCT2026Nat Med
Dietary Supplement Considerations During Glucagon-Like Peptide-1 Receptor Agonist Treatment
Review2025
Effects of Retatrutide on Body Composition in People with Type 2 Diabetes: A Phase 2 Substudy
Phase II RCT Substudy2025Lancet Diabetes Endocrinol
Body Composition Changes During Weight Reduction with Tirzepatide in the SURMOUNT-1 Study
Phase III RCT Substudy2025
The Impact of Weight Loss on Fat-Free Mass, Muscle, Bone and Hematopoiesis Health: Implications for Emerging Pharmacotherapies
Review2024Metabolism
Strategies for Minimizing Muscle Loss During Use of Incretin-Mimetic Drugs for Treatment of Obesity
Review2025Obes Rev
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
Review2024Diabetes Care
A Systematic Review of the Effect of Semaglutide on Lean Mass: Insights from Clinical Trials
Systematic Review2024
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined (S-LITE Trial)
Randomized Controlled Trial2021N Engl J Med
Effects of Energy-Restricted High-Protein vs Standard-Protein Diets: A Meta-Analysis of 24 RCTs
Meta-Analysis2012Am J Clin Nutr
Peptides in This Article
Related Reading
The Most Popular Peptides of 2026
From oral GLP-1 pills and triple agonists to the FDA reclassification saga and a copper peptide going viral — what's driving 10 million monthly peptide searches.
Foundayo vs Oral Wegovy: The Battle of the GLP-1 Pills
Eli Lilly's small-molecule pill vs Novo Nordisk's peptide tablet. One is more convenient, the other more effective. Here's what the data shows — and why no head-to-head trial exists yet.
Will Peptides Work for Me? What Genetics, Sex, and Phenotype Tell Us
A landmark 2026 Nature study of 27,885 people found genetic variants that predict GLP-1 drug response. But genetics is just one piece — here's the full picture of why peptides work differently for different people.